Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACEPHEN vs DUZALLO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
DUZALLO (allopurinol) is a xanthine oxidase inhibitor that reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Mild to moderate pain,Fever
Management of signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy),Prevention of tumor lysis syndrome in patients receiving chemotherapy for leukemia, lymphoma, or solid tumor malignancies
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Adults: 200 mg orally twice daily.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Terminal elimination half-life is approximately 12 hours (range 10–14 hours), allowing twice-daily dosing for steady-state achievement within 2–3 days.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily metabolized by aldehyde oxidase to oxipurinol, the active metabolite. Also metabolized via xanthine oxidase. Bioactivation requires hepatic metabolism.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Primarily renal excretion (approximately 70% as unchanged drug); biliary/fecal excretion accounts for about 20%; the remainder undergoes hepatic metabolism.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Approximately 95% bound primarily to albumin and alpha-1-acid glycoprotein.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Volume of distribution is 0.3–0.5 L/kg, indicating distribution primarily into extracellular fluid and well-perfused tissues.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Oral bioavailability is 60%–70% (first-pass metabolism); intravenous bioavailability is 100%.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Not recommended in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²). No dose adjustment required for mild to moderate impairment (e GFR ≥ 30 m L/min/1.73 m²).
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not recommended in moderate or severe hepatic impairment (Child-Pugh B or C).
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Safety and efficacy not established in pediatric patients (< 18 years).
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
No specific dose adjustment required; monitor renal function due to age-related decline.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
There is no FDA black box warning for DUZALLO.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis,Acute gout flare upon initiation; may require prophylactic anti-inflammatory therapy,Renal impairment: dose adjustment required,Hepatic toxicity may occur,Elevated risk of skin rash with concurrent amoxicillin or ampicillin use
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Hypersensitivity to allopurinol or any component of the formulation,Concomitant use with didanosine
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition increasing elagolix levels. High-fat meals may slightly increase elagolix absorption but no dose adjustment needed. No other significant food interactions reported.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
DUZALLO (allopurinol) is generally considered low risk. First trimester: limited data, no increased malformations. Second/third trimester: no known fetal harm. However, use only if clearly needed.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Allopurinol and its metabolite oxypurinol are excreted into breast milk. M/P ratio: 1.4 for allopurinol, 2.5 for oxypurinol. No adverse effects reported in infants; compatible with breastfeeding, but monitor infant for rash.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
No specific dose adjustments recommended for pregnancy. Monitor renal function; reduce dose if creatinine clearance decreases. Standard adult dosing: 100-300 mg/day, may be increased up to 800 mg/day under guidance.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
DUZALLO (elagolix/estradiol/norethindrone acetate) is a Gn RH antagonist combination product for management of heavy menstrual bleeding in premenopausal women with uterine leiomyomas. Monitor bone mineral density with prolonged use beyond 6 months; avoid in patients with osteoporosis risk factors. Contraindicated with strong CYP3A4 inhibitors and in pregnancy. Assess for mood changes and depression. Use effective non-hormonal contraception during treatment.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
Take one tablet daily at approximately the same time with or without food.,Missing doses increases risk of pregnancy and reduces effectiveness for bleeding control.,Use effective non-hormonal contraception (e.g., condoms, copper IUD) during treatment and for 2 weeks after discontinuation.,Report severe headache, chest pain, or vision changes immediately (risk of thromboembolic events).,Notify your doctor if you suspect pregnancy or develop heavy bleeding, worsening depression, or jaundice.,Bone density may decrease; calcium and vitamin D supplementation is recommended.,Avoid grapefruit or grapefruit juice during treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACEPHEN vs DUZALLO, answered by our medical review team.
ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. DUZALLO is a Xanthine Oxidase Inhibitor that works by DUZALLO (allopurinol) is a xanthine oxidase inhibitor that reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACEPHEN and DUZALLO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of DUZALLO is: Adults: 200 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACEPHEN and DUZALLO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. DUZALLO is classified as Category C. DUZALLO (allopurinol) is generally considered low risk. First trimester: limited data, no increased malformations. Second/third trimester: no known fetal harm. However, use only if. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.